Delivering Transformative Medicines
Exopharm (ASX: EX1) is a clinical-stage company at the forefront of developing transformative exosome medicines. Our mission is to be a global leader in exosome-based therapeutics.
Using exosomes to deliver transformative medicines
- Enabling Biopharma companies to deliver new and existing drug candidates in novel ways
- Designing and evaluating entirely new exosome medicines
Partner with Exopharm to meet your exosome medicine goals
- Solve delivery problems with existing ‘stranded assets’
- Target loaded drugs to specific cell types (i.e. confer tropism)
- Deliver drugs across biological barriers, including the blood brain barrier
Exosomes are nano-sized particles produced by most animal cells to exchange materials and genetic instructions and co-ordinate cellular activities in our bodies. For some medicines, exosomes are an alternative and superior means for delivery inside the body.
Exopharm has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types.
Exopharm’s LEAP manufacturing technology provides access to large quantities of high-purity exosomes for research and clinical uses.
Exopharm is a publicly traded company on the Australian Securities Exchange under code ASX:EX1.
Visit our Resources section for ASX announcements, investor information, news and articles.
Under News and Articles, access more information about exosomes, news, whitepapers and opinion articles. Also find links to past talks and webinars.
An experienced and dedicated team
Founded in 2013 by Dr Ian Dixon on the LEAP Technology, Exopharm has built a highly skilled team with broad manufacturing, scientific and commercial expertise. Our success would not be possible without the exceptional minds working together behind the scenes with a range of capabilities across specialised areas.